Get the Stockscreener App
542.12
2.43%
-13.48
After Hours:
539.10
-3.02
-0.56%
Madrigal Pharmaceuticals Inc stock is traded at $542.12, with a volume of 270.55K.
It is down -2.43% in the last 24 hours and up +23.22% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$555.60
Open:
$562.71
24h Volume:
270.55K
Relative Volume:
0.77
Market Cap:
$12.04B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-21.58
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
+5.28%
1M Performance:
+23.22%
6M Performance:
+85.18%
1Y Performance:
+70.97%
1-Day Range:
$540.01
$571.16
1-Week Range:
$505.00
$577.90
52-Week Range:
$265.00
$577.90
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
542.12 | 12.62B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Madrigal Pharmaceuticals (NASDAQ: MDGL) grants 2,125 RSUs to hires under inducement plan - Stock Titan
Jefferies 25: The Cardiometabolic Revolution Is Going Global - Citeline News & Insights
Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating - MarketScreener
What margin trends mean for Madrigal Pharmaceuticals Inc. stockChart Signals & Momentum Based Trading Ideas - newser.com
Madrigal Pharmaceuticals (MDGL): Oppenheimer Raises Price Target - GuruFocus
Oppenheimer raises Madrigal Pharmaceuticals stock price target on positive Rezdiffra data - Investing.com Canada
Will Madrigal Pharmaceuticals Inc. stock pay special dividendsJuly 2025 PostEarnings & Pattern Based Trade Signal System - newser.com
Is Madrigal Pharmaceuticals Inc. (YDO1) stock in buy zone after pullbackPortfolio Return Report & Low Volatility Stock Suggestions - newser.com
How Madrigal Pharmaceuticals Inc. (YDO1) stock reacts to Fed tighteningJuly 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
Why Madrigal Pharmaceuticals Inc. (YDO1) stock is listed among top recommendationsTrade Ideas & Real-Time Price Movement Reports - newser.com
Madrigal Pharmaceuticals stock price target raised by Truist on MASH potential - Investing.com South Africa
Can Madrigal Pharmaceuticals Inc. stock sustain market leadershipTrade Entry Report & Safe Entry Trade Signal Reports - newser.com
Madrigal Pharmaceuticals (MDGL) Rating Maintained and Price Target Raised by Truist Securities | MDGL Stock News - GuruFocus
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsJuly 2025 Selloffs & Safe Entry Point Identification - newser.com
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stockWall Street Watch & Accurate Entry/Exit Alerts - newser.com
Truist Raises Price Target on Madrigal Pharmaceuticals to $640 From $580, Keeps Buy Rating - MarketScreener
How Madrigal Pharmaceuticals Inc. (YDO1) stock performs in volatility spikes2025 Short Interest & Long-Term Safe Investment Plans - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock extend growth storyWeekly Trend Summary & Safe Entry Trade Signal Reports - newser.com
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Visual analytics tools that track Madrigal Pharmaceuticals Inc. performanceMarket Growth Report & Fast Gain Stock Tips - newser.com
Is it too late to sell Madrigal Pharmaceuticals Inc.July 2025 Sector Moves & Daily Entry Point Trade Alerts - newser.com
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones - Yahoo Finance
Madrigal Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Madrigal Pharmaceuticals (MDGL) Is Up 5.7% After Positive Phase 3 Rezdiffra Results in Advanced MASH Cirrhosis - Yahoo Finance
Will Madrigal Pharmaceuticals Inc. (YDO1) stock sustain dividend payoutsWall Street Watch & Low Risk High Reward Ideas - newser.com
Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)? - Yahoo Finance
Breakthrough Liver Drug Shows Powerful Two-Year Gains — But Raises a Critical Warning - MyChesCo
Madrigal Pharmaceuticals stock hits all-time high at 545.0 USD By Investing.com - Investing.com UK
Madrigal Pharma (NASDAQ: MDGL) sets fireside chats at three investor conferences - Stock Titan
How to escape a deep drawdown in Madrigal Pharmaceuticals Inc.2025 Top Gainers & Community Verified Swing Trade Signals - newser.com
Madrigal Pharmaceuticals (BIT:1MDGL) Price Target Increased by 11.64% to 485.78 - Nasdaq
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):